Key Points
- Insider buying: Fiorenzo Villani purchased 4,265 Portage Biotech shares at an average price of $4.05, increasing his position by 12.32% to 38,886 shares. He also made four additional purchases in September.
- Stock performance and finances: ALP opened at $4.50, up 9.8%, but has a market capitalization of approximately $6.97 million and weak liquidity ratios, including a 0.31 current ratio.
- Analyst outlook: Analysts have a consensus “Reduce” rating, with two Hold ratings and one Sell rating, despite an average price target of $12.50.
Portage Biotech Inc. (NASDAQ:ALP - Get Free Report) insider Fiorenzo Villani bought 4,265 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The stock was purchased at an average cost of $4.05 per share, with a total value of $17,273.25. Following the acquisition, the insider directly owned 38,886 shares in the company, valued at $157,488.30. This trade represents a 12.32% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Fiorenzo Villani also recently made the following trade(s):
- On Tuesday, September 15th, Fiorenzo Villani purchased 7,900 shares of Portage Biotech stock. The shares were acquired at an average cost of $4.15 per share, for a total transaction of $32,785.00.
- On Tuesday, September 15th, Fiorenzo Villani acquired 10,382 shares of Portage Biotech stock. The stock was acquired at an average price of $4.07 per share, for a total transaction of $42,254.74.
- On Monday, September 14th, Fiorenzo Villani bought 2,000 shares of Portage Biotech stock. The shares were acquired at an average price of $4.16 per share, with a total value of $8,320.00.
- On Wednesday, September 9th, Fiorenzo Villani bought 7,000 shares of Portage Biotech stock. The shares were acquired at an average cost of $5.07 per share, for a total transaction of $35,490.00.
Portage Biotech Stock Up 9.8%
Shares of ALP opened at $4.50 on Friday. The business's 50 day moving average is $9.78 and its 200 day moving average is $14.39. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.01. Portage Biotech Inc. has a 12-month low of $3.20 and a 12-month high of $690.00. The company has a market capitalization of $6.97 million, a PE ratio of -0.01 and a beta of 0.54.
Portage Biotech (NASDAQ:ALP - Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The company reported $23.75 earnings per share for the quarter. The business had revenue of $0.05 million during the quarter. Research analysts expect that Portage Biotech Inc. will post -14 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts recently weighed in on ALP shares. HC Wainwright assumed coverage on shares of Portage Biotech in a research note on Monday, August 17th. They set a "neutral" rating and a $12.50 target price for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Portage Biotech in a report on Friday, July 24th. Zacks Research upgraded Portage Biotech to a "hold" rating in a research report on Tuesday, August 18th. Finally, Wall Street Zen raised Portage Biotech to a "hold" rating in a research note on Saturday, September 12th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Reduce" and an average target price of $12.50.
Check Out Our Latest Report on ALP
About Portage Biotech
(
Get Free Report)
Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.
Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
